R-I next interim look, and perhaps even V approval in 2018, will be complete before any of the investigations and other events with respect to other companies you mention will be completed. You have not persuaded me that any of the events you mention will have an earlier effect on Amarin share price than interim look or news of next supplemental filings with FDA per settlement agreement with FDA. An earlier buy out offer or SEC filing by other companies are cards on the table having the potential to also affect share price.
Market Data 
Markets 
AI
